Cara Therapeutics Reports First Quarter 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Cara Therapeutics (CARA) Misses Q1 EPS by 7c
May 4, 2017 4:24 PM EDTCara Therapeutics (NASDAQ: CARA) reported Q1 EPS of ($0.81), $0.07 worse than the analyst estimate of ($0.74). Revenue for the quarter came in at $843 thousand versus the consensus estimate of $150 thousand.
For earnings history and earnings-related data on Cara Therapeutics (CARA) click here.
... More